Key Points
- Ra Capital Management, L.P., a Vor Biopharma director, sold 165,150 shares on April 22 at $15.77 for $2.60M — part of a string of April sales that reduced its ownership by 6.43% to 2,402,095 shares valued at about $37.9M.
- Vor Biopharma stock opened at $13.81 (50‑day/200‑day averages $14.89/$15.65) with a $674.6M market cap, and analysts carry a “Moderate Buy” consensus and an average target price of $50.56 despite mixed ratings.
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the transaction, the director owned 2,402,095 shares of the company's stock, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, April 20th, Ra Capital Management, L.P. sold 171,963 shares of Vor Biopharma stock. The shares were sold at an average price of $15.77, for a total value of $2,711,856.51.
- On Friday, April 17th, Ra Capital Management, L.P. sold 458,411 shares of Vor Biopharma stock. The shares were sold at an average price of $16.28, for a total value of $7,462,931.08.
- On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total value of $8,569,351.50.
- On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total value of $858,840.44.
- On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total value of $2,455,147.95.
- On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total value of $13,041.00.
- On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59.
- On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92.
- On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
- On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00.
Vor Biopharma Price Performance
Shares of Vor Biopharma stock opened at $13.81 on Friday. The business has a 50-day moving average of $14.89 and a 200 day moving average of $15.65. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The stock has a market capitalization of $674.62 million, a price-to-earnings ratio of -0.04 and a beta of 1.92.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on VOR shares. Wedbush raised their target price on Vor Biopharma to $15.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wall Street Zen raised Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Saturday, April 4th. Citigroup began coverage on Vor Biopharma in a research report on Friday, January 9th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, HC Wainwright reduced their price target on Vor Biopharma from $32.00 to $31.00 and set a "buy" rating on the stock in a research report on Wednesday, April 15th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Vor Biopharma has an average rating of "Moderate Buy" and an average target price of $50.56.
View Our Latest Research Report on VOR
Institutional Investors Weigh In On Vor Biopharma
Several hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in Vor Biopharma during the 4th quarter worth approximately $36,000. Bank of America Corp DE grew its stake in Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock worth $232,000 after buying an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Vor Biopharma during the 3rd quarter worth approximately $230,000. BNP Paribas Financial Markets grew its stake in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock worth $296,000 after buying an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in Vor Biopharma during the 3rd quarter worth approximately $304,000. Institutional investors and hedge funds own 97.29% of the company's stock.
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
